TABLE 1.

Select retrospective series of thrombosis in patients receiving immunotherapy

Author	Number of patients	Type of malignancy	Type of immunotherapy	VTE incidence	ATE incidence
Moik et al.26	672	Melanoma (30.4%), non-small-cell lung cancer (24.1%), renal cell carcinoma (11.0%), head and neck squamous cell carcinoma (10.4%), and urothelial cancer (4.9%)	Nivolumab (42.0%), pembrolizumab (40.0%), ipilimumab (6.7%), ipilimumab and nivolumab (6.0%), atezolizumab (30, 4.5%), and avelumab (0.9%)	12.9%	1.8%
Sussman et al.21	228	Melanoma	Pembrolizumab (38.7%), ipilimumab plus nivolumab (29.4%), ipilimumab (20%), and nivolumab (12.3%)	16.2%	6.1%
Roopkumar et al.25	1686	Lung (49.6%) and melanoma (13.2%)	Nivolumab, pembrolizumab, atezolizumab, ipilimumab, avelumab, durvalumab, nivolumab, and ipilimumab	24%	N/A
Icht et al.23	345 (but only 176 received immunotherapy)	NSCLC	ICIs	4.5%	N/A
Ando et al.29	122	Lung cancer, kidney cancer, stomach cancer, urothelial carcinoma, or malignant melanoma	Nivolumab (N = 85) or pembrolizumab (N = 37)	4.1%	4.9%
Gutierrez-Sainz et al.28	229	Lung cancer (48.0%), melanoma (23.6%), and renal cell carcinoma (11.8%)	Pembrolizumab (40.2%) and nivolumab plus ipilimumab (8.4%)	7%	N/A
Guven et al.27	133	Renal cell carcinoma (26.3%) and melanoma (24.1%)	ICI	11.3%	N/A
Deschênes-Simard et al.22	593	NSCLC	Anti-PD-1 (91.9%), with nivolumab (53.5%)	9.9%	1.3%
Ibrahimi et al.30	154	Lung cancer (20.8%), melanoma (20.1%), and ovarian cancer (12.3%)	Nivolumab (47.4%), pembrolizumab (22.7%), other investigational agents (22.7%), and atezolizumab (7.2%)	10%	0%